Chardan Capital Keeps Their Buy Rating on uniQure (QURE)

By Austin Angelo

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QUREResearch Report) today and set a price target of $125.00. The company’s shares closed last Monday at $66.70.

According to, Amusa is a top 100 analyst with an average return of 26.9% and a 52.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Axovant Gene Therapies, and Minerva Neurosciences.

uniQure has an analyst consensus of Strong Buy, with a price target consensus of $78.25, which is a 15.9% upside from current levels. In a report issued on December 3, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $98.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $82.49 and a one-year low of $24.07. Currently, uniQure has an average volume of 512.9K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.